{"groups":[{"description":"Participants received 0.4x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG000","title":"Arm 1 Dose Escalation Dose Level (DL) -1 - 0.4x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 0.75x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG001","title":"Arm 1 Dose Escalation (Esc) Dose Level 1 - 0.75x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 1.5x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG002","title":"Arm 1 Dose Escalation Dose Level 2 - 1.5x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 3.0x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG003","title":"Arm 1 Dose Escalation Dose Level 3 - 3.0x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 6.0x10\\^6 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG004","title":"Arm 1 Dose Escalation Dose Level 4 - 6.0x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 12.0x1\\^06 Chimeric Antigen Receptor (CAR)+ T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.","id":"FG005","title":"Arm 1 Dose Escalation Dose Level 5 - 12.0x1^06 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Participants received 6.0x10\\^6 (maximum feasible dose) CAR+T cells per kg + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG006","title":"Arm 2 Dose Expansion (Exp) 6.0x10^6 Chimeric Antigen Receptor (CAR)+ T Cells Per kg"},{"description":"Dose Escalation: Participants received 3.0x10\\^6 CAR+T cells per kg infused on day 0 + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg /m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3.\n\nAND\n\nDose Expansion:\n\nParticipants received 6.0x10\\^6 (maximum feasible dose) CAR+T cells per kg + Cyclophosphamide: 300 mg/m\\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m\\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3","id":"FG007","title":"Arm 1 DoseEsc DL 3-3.0x10^6 CAR+T Cells Per kg Followed by Arm 2 DoseExp 6.0x10^6 CAR+T Cells Per kg"},{"description":"Participants was enrolled but not treated.","id":"FG008","title":"Participants Enrolled in Arm 1 But Not Treated"},{"description":"Participants was enrolled but not treated.","id":"FG009","title":"Participants Enrolled in Arm 2 But Not Treated"}],"periods":[{"milestones":[{"achievements":[{"comment":"No participants were enrolled in this Arm/Group.","groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"8"},{"groupId":"FG009","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"8"},{"groupId":"FG009","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Dose Escalation Phase"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"8"},{"groupId":"FG007","numSubjects":"1"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Expansion Phase"}]}